Dermapharm Holding SE (DMP.DE)

47.14 €

+0.20 (+0.43%)
Rating:
Recommendation:
-
Symbol DMP.DE
Price 47.14 €
Beta 1.187
Volume Avg. 0.03M
Market Cap 2.538B
Shares () -
52 Week Range 34.3-59.6
1y Target Est -
DCF Unlevered DMP.DE DCF ->
DCF Levered DMP.DE LDCF ->
ROE 35.41% Strong Buy
ROA 12.13% Buy
Operating Margin -
Debt / Equity 187.73% Buy
P/E 14.42 Strong Buy
P/B 5.03 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades


Dr. Hans-Georg Feldmeier
Healthcare
Drug Manufacturers—Specialty & Generic
Frankfurt Stock Exchange

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.